Object. Bilateral subthalamic nucleus (STN) stimulation is increasingly used in patients with advanced Parkinson disease (PD). This study was performed to evaluate the long-term efficacy and safety of bilateral STN stimulation in cases of PD.
ONG-TERM treatment of PD with levodopa is complicated by motor fluctuations and dyskinesias. 8 Early in the course of the disease these motor fluctuations and dyskinesias can be managed by adjustments in medication; however, as the disease progresses the symptoms become increasingly more difficult to manage and can result in marked disability. Often these symptoms cannot be managed with medications. Surgery, especially bilateral STN stimulation, is increasingly used for the management of these motor fluctuations and dyskinesias. 2 Bilateral STN stimulation was approved by the US Food and Drug Administration in January 2002. There are multiple reports on the efficacy and safety of bilateral STN stimulation in patients with PD who experience disabling motor fluctuations and dyskinesias. 2, [5] [6] [7] [9] [10] [11] 13, 15, 19, 20 The majority of these reports contain descriptions of small series of patients with a usual follow-up period of 12 months (Table 1) . Some centers have reported on small numbers of patients with longer follow-up periods, in which the short-term efficacy of STN stimulation was maintained. 1, 16, 17 We prospectively evaluated our patients with PD who underwent bilateral STN stimulation surgery 1 and 2 years postoperatively.
Clinical Material and Methods

Patient Population
All patients were recruited from the Parkinson's Disease Clinic of the University of Kansas Medical Center. The criteria for surgery included the presence of at least two cardinal features of PD (tremor, rigidity, and bradykinesia); responsiveness to levodopa in patients with medication-resistant motor fluctuations and dyskinesias, or the presence of medication-resistant disabling tremor; and patient age younger than 80 years. Exclusion criteria included cognitive impairment (Mattis Dementia Rating Scale score Ͻ 120); major psychiatric or behavioral illness; presence of a cardiac pacemaker; and significant medical problems. Three of the patients underwent surgery as part of a multicenter DBS protocol; 2 the remaining patients underwent surgery because their conditions seemed appropriate for off-label treatment provided by an approved device. All operations were performed by the same neurosurgeon (S.B.W.) and all patients were evaluated by the same neurologist specializing in movement disorders (R.P.). All patients who underwent surgery were asked to return for follow-up evaluations. The protocol was approved by the institutional review board. All patients provided written informed consent for participation in the data collection.
Surgical Procedure
A Cosman-Roberts-Wells (Radionics, Inc., Burlington, MA) or Leksell G (Elekta, Inc., Atlanta, GA) stereotactic head frame was placed on the patient after local anesthesia had been induced. Computerized tomography scanning was used for targeting in the initial 17 patients; thereafter, MR imaging was exclusively used. When the Leksell frame was selected for the procedure, the computerized tomography and MR images that were obtained were downloaded into the Leksell Surgiplan system. The software reformats the image, compensating for pitch, yaw, and roll, and then displays the image aligned normal to the screen. The target was defined 12 mm lateral to the midpoint of the AC-PC line. The vertical coordinate was 5 mm inferior to the AC-PC plane. After a local anesthetic agent had been administered, a burr hole was created 3 cm from the midline, anterior to the coronal suture on each side. Microelectrode recording and stimulation techniques were used to refine the target further. Once an optimal position was selected, macrostimulation was performed using a 1.1 ϫ 3-mm exposed-tip electrode to determine if there were any side effects associated with the stimulation or if any benefits accrued such as a reduction in tremor, bradykinesia, or rigidity. If no side effects were demonstrated, the DBS electrode (model 3387 or model 3389; Medtronic, Inc., Minneapolis, MN) was implanted in the same location. Fluoroscopy was used to ensure that the implanted electrode was in the same depth location as the macroelectrode. Stimulation was again produced through the implanted electrode to confirm that there were no side effects. The DBS electrode was secured at the burr hole site. An extension was attached to the DBS electrode and tunneled out posteriorly with respect to the wound. The connection and the excess DBS electrode were buried in the subgaleal space. Electrodes were implanted into each hemisphere during the same procedure. 
Stimulation Settings
Programming was initiated while the patient was in the medication-off state.
14 In the initial group of patients DBS was started immediately after surgery; however, in the last 2 years we did not initiate programming until 4 to 6 weeks after surgery. The electrodes were first screened in the range of parameters recommended by the manufacturer to provide patient comfort and suppression of symptoms. Screening was used to evaluate four monopolar and 12 bipolar polarity combinations for an anatomically specific site response to the stimulation threshold and the maximal tolerated stimulation. Based on the screening results, the programmer selected the electrode or electrode combination with the best preliminary benefit, the fewest adverse effects, and the largest therapeutic window between symptom suppression and adverse effects. Selection of voltage, frequency, and stimulus duration were dependent on patient responses. Reprogramming of the stimulation system was performed during the study if there was a loss of benefit or adverse effects associated with the stimulation.
Clinical Evaluation of Patients
Clinical evaluations included application of the UPDRS, 3 the Schwab and England Scale, 18 the Hoehn and Yahr staging, 4 and a timed tapping task. 12 Tapping tests were used to measure the number of times per minute that the patients could alternatively tap two manual counters located 20 cm apart. This served as an index of bradykinesia. Unblinded and baseline evaluations were performed while the patient was in the medication-off state (at least 12 hours after withdrawal of antiparkinsonian medication) and again while the patient was in the medication-on state (when the patient was in his or her best motor state after a morning dose of antiparkinsonian medication). These evaluations were performed within 30 days before surgery and the antiparkinsonian medications were not altered prior to the operation. Unblinded postoperative evaluations were performed with the stimulators on and the patient in both the medicationoff and medication-on states. These evaluations were performed approximately 3 months, 12 months, and annually after surgery. The patients also completed a home diary, documenting their status at 30-minute intervals for 2 consecutive days before evaluation visits. The patients noted whether they were in the medication-off state, medicationon state, medication-on state with dyskinesias, or asleep during the day. After surgery, dopaminergic therapy was adjusted based on the patient response to stimulation, resulting in an improvement in the parkinsonian symptoms. Dopaminergic therapy was adjusted after stimulation was initiated and while adjustments were made to the devices. Levodopaequivalent doses were calculated to reflect the change in dosage brought about by surgery as follows: 100 mg of standard levodopa = 125 mg of controlled-release levodopa = 10 mg of bromocriptine = 1 mg of pergolide = 1 mg of pramipexole = 3 mg of ropinirole. Selegiline, anticholinergic agents, amantadine, entacapone, and tolcapone were not included in these calculations.
Statistical Analysis
Efficacy analyses included the effect of stimulation on the changes between baseline and 2-year postoperative UPDRS ADL and motor scores, tapping total in the medication-off and medication-on states; reduction in the length of the medication-off states, as measured by patient diaries; changes in scores of the UPDRS subtests (tremor Mean values for parametric measures were compared using t-tests, and mean values for nonparametric measures were analyzed by applying Wilcoxon signed rank comparisons. A probability value less than 0.05 was considered statistically significant.
Results
Seventy-two patients with PD underwent bilateral implantation of STN stimulators between 1997 and 2002. Patients with at least 1 year postoperative follow-up evaluation and no previous surgery for a cranial lesion were included in the study (35 patients and 70 surgeries). Seventeen patients have not yet reached the 1-year follow-up evaluation, eight patients previously underwent ablative surgery, five patients were lost to follow up, three patients underwent unilateral surgery, one patient was only using one side of the body, two patients died before the 1-year follow-up visit (due to unrelated causes), and in one patient the stimulation system was removed because of infection and was not reimplanted.
Of the 35 patients included in the study, there were 22 men and 13 women. The mean age of the patients was 58.4 years (range 35-76 years) and the mean duration of their disease was 12 years (range 3.9-27.2 years). We divided our cohort into those patients with 1-year follow-up review (33 patients; two patients missed the 1-year evaluation but returned for the 2-year evaluation) and those patients who participated in the 2-year follow-up review (19 patients).
One-Year Cohort. In this group there were 33 patients, 21 men and 12 women. The mean age of these patients was 58.5 years (range 35-75 years) and the mean duration of their disease was 11.8 years (range 5.7-23.3 years). The mean improvement in baseline UPDRS motor scores after the levodopa challenge (UPDRS motor scores in the patients in the medication-off state compared with UPDRS motor scores in the same patients in the medication-on state) was 40.4%. There was a 38.1% improvement when the baseline medication-off UPDRS motor scores were compared with the medication-off/stimulation-on scores at 1 year postoperatively. The results of the other evaluations, including UPDRS subscores, are shown in Table 2 .
Two-Year Cohort. In this group there were 19 patients, 12 men and seven women with a mean age of 56.4 years (range 35-76 years) and a mean disease duration of 12.1 years (range 3.9-27.2 years). The mean duration of followup review was 27.8 months (range 22-42 months). The baseline levodopa challenge resulted in a 36.6% improvement in the patient's UPDRS motor scores. There was a 27.8% improvement in the UPDRS motor medication-off/ stimulation-on scores, compared with the baseline medication-off scores. The results of the other evaluations, including the UPDRS subscores, are shown in Table 3 . Compared with baseline, stimulation in patients in the medicationoff state resulted in a significant improvement in UPDRS motor scores. Stimulation in patients in the medicationoff state also resulted in significant improvements in the UPDRS ADL (p = 0.001) and tremor (p = 0.002) scores. Assessments of patient diaries showed a significant improvement during the medication-on state (p = 0.002) ( Table  4 ). The percentages of improvement in UPDRS subscores while patients were in the medication-on and -off states are shown in Fig. 2 . Stimulation Parameters. The stimulation settings for the two hemispheres are shown in Tables 2 and 3 . During the period of the study the amplitude, pulse width, and frequency increased on both sides, although these increases were not significant.
Adverse Effects. Adverse effects are reported for all 35 patients. Surgical complications were defined as those that occurred within 30 days postoperatively. Three patients had seizures, five displayed confusion, one patient experienced visual disturbances, and one patient experienced hemiballismus. All these adverse effects resolved. Surgery was aborted in two patients, one who experienced visual disturbances and another in whom stimulation produced no effect in the operating room. Later, both these patients successfully underwent the procedure.
Adverse effects due to stimulation were mild and could be controlled by an adjustment in the stimulation parameters. These included dysarthria in 10 patients, gait abnormality in three, paresthesias in two, depression in one, and muscle spasms in one patient (the electrode was revised in the last patient, resulting in improvement in his muscle spasms).
Eighteen patients experienced no device-related events. The device-related events for the remaining 17 patients were grouped by the year of the initial surgery. In 1997, three patients underwent surgery. The first patient needed a replacement lead because no benefit was gained with stimulation. The second patient required two replacement leads because the originals had been placed in the wrong position. An infection later developed in that patient and both leads, extension, and IPG had to be explanted; finally both leads were replaced. In the third patient one lead was revised and another lead replaced; an IPG and extension were also replaced because of intermittent stimulation. This patient's other extension was replaced 3 years after the initial surgery because of fracture. In 1998, only one patient underwent surgery and no device-related events occurred. In 1999, 16 patients received stimulators and the following events occurred in 11 of those patients. Four leads were replaced, three because of a lack of benefit and one because of fracture, and five leads were revised because of a lack of benefit. There were two infections; one required the DBS system to be explanted on one side and later replaced, and the other required explantation and replacement of the IPG and extension. Two extensions were replaced, one because of skin erosion and another because of fracture. Nine IPGs needed to be replaced, three because of dead batteries and six because of malfunction. In 2000 and 2001 15 patients who underwent surgery were included in the study. One lead was revised because of a lack of benefit, one lead was replaced because of adverse effects, and one IPG was replaced because it was malfunctioning.
Discussion
Our data demonstrate that bilateral DBS of the STN in patients with PD who experience medication-resistant motor fluctuations and dyskinesias results in a significant improvement in medication-off UPDRS motor and ADL scores, and improvement in the medication-on state during the day, as well as a significant reduction in required antiparkinsonian medication units. These benefits continue for up to 28 months of follow-up review.
Although our results show improvements similar to those reported by other authors, the percentage of improvement differs across various studies (Table 1) . 2, [5] [6] [7] [9] [10] [11] 13, 15, 19, 20 Using patient diaries we recorded a 61% reduction in medication-off time at 2 years postoperatively. PD Study Group showed a reduction of 61% in the length of the medication-off state at 6 months postoperatively by using patient diaries, an improvement which was similar to our results at 28 months.
Krack and colleagues 6 have stated that the improvement in all motor symptoms associated with bilateral STN is very close or equal to the response to levodopa. In published studies authors have reported a wide range of improvement, 45 to 71%, in UPDRS motor scores among patients in the medication-off state in response to stimulation. The levodopa challenge in these studies also varies in the rates of improvement, from 46 to 73%. Our patients at 2 years had a smaller improvement (28%) in UPDRS motor scores, but the improvement in UPDRS motor scores during the levodopa challenge was also smaller (37%) than those reported for other studies. It is recommended that patients display at least a 33% improvement in UPDRS motor scores to be considered for STN surgery.
When we initially began to perform STN DBS, we evaluated patients for improvement by giving them the levodopa challenge, but did not apply a minimum percentage of improvement for patients to be considered for surgery. Presently, we use a 30% improvement in the UPDRS motor scores as a consideration for the selection of patients for surgery. Our smaller percentage of improvement in UPDRS motor scores in response to the levodopa challenge could partly be related to patient selection; however, the examiner bias inherent in the performance of open-label evaluations cannot be ruled out. Another possible reason why our patients did not have the percentage of improvement reported for other studies could be due to the fact that our patients were not as initially disabled as those participating in other studies. The UPDRS motor scores in the medication-off state at baseline in those studies varied from 44 to 60 in comparison with our mean baseline score of 41.3 (Table 1 ).
In addition, we believe that there is a learning curve for both the neurologist and the neurosurgeon, which over time results in improvements in outcome with better patient selection and increased surgical experience. Technological changes that occur over time may also contribute to improvements in outcome. This can be evaluated by comparing our 1-year cohort with our 2-year cohort. Our 1-year cohort includes more recently recruited patients who have not yet undergone their 2-year evaluations. Not only does this group demonstrate a more robust response to the levodopa challenge (40.4%), but also a comparable improvement in response to DBS (38.1%).
The UPDRS motor scores measured while patients were in the medication-on state did not change significantly in our patients receiving DBS. Although there was an improvement in tremor scores, this was not significant. Variations in patient responses in other studies have ranged from an 8% rate of symptom worsening in one study to a 54% rate of symptom improvement in patients in the medicationon state in another. Medication-on state evaluations have been performed differently by various authors. For example, in the study by Ostergaard, et al., 13 the medication-on/ stimulation-on evaluations were performed 90 minutes after patients received their antiparkinsonian medications (60 minutes after the medication was distributed the devices were turned on). Some patients with advanced PD may not experience the medication-on state 90 minutes after they have taken their medication because the medication may not have taken effect by that time. In addition, a patient's medication is frequently reduced postsurgery and, therefore, it is often very difficult for the medication to produce a therapeutic effect when taken without stimulation.
Surgery-and stimulation-related adverse effects were uncommon in our series. We did not have any intracranial episodes of bleeding. There was a 4.3% risk of postoperative seizures (three of 70 procedures). All seizures occurred within 24 hours after surgery and were self limiting; patients did not require long-term treatment with anticonvulsant medications. There was a similar risk of infection. These surgical risks are similar to those seen in some other series. 2, 19 On the other hand, the number of device-related events in our series was higher than those reported by other investigators. The majority of these events occurred in the first 20 patients included in the study. Although this is due in part to the learning curve involved, we also believe that certain technological changes have reduced the number of repeated surgeries. These include a change in the location at which the extension is anchored, resulting in fewer extension fractures; the use of fluoroscopy to monitor electrode depth movement during fixation, and the Navigus Cap (Model DB-1000; Image Guided Neurologics, Melbourne, FL), which better anchors the lead. All these changes have contributed to fewer lead revisions and replacements due to incorrect electrode location from migration of the lead during and after wound closure. Of these changes, fluoroscopy seemed to have the largest impact on reducing device-related complications because the majority of these were related to the lead position. In our series, there were no complications related to lead placements after fluoroscopy was performed. In addition, the change from the Itrel II to the Soletra IPG has seemingly resulted in fewer IPG malfunctions.
Conclusions
Bilateral STN stimulation is an effective and safe longterm treatment for patients with PD who experience medication-resistant motor fluctuations or tremor. It results in significant reductions in the percentage of medication-off time during the day and in medication-off state UPDRS motor scores and ADL scores. These improvements are maintained up to 2 years. Although there were a large number of device-related events in the first 20 patients included in our study, this number was dramatically reduced with the increased experience of the surgical team, modification of fixation techniques, and technological advances in the IPG used. Clinicians at centers contemplating performing surgery for DBS of the STN should be aware of these potential problems.
